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overall SAS score (P  0.001). Baseline to week 4 differ-
ences in overall SAS demonstrate significantly greater im-
provement for nefazodone mono-therapy compared to
CBASP mono-therapy (P  0.032). Conservative esti-
mates of mean direct treatment costs per patient irrespec-
tive of response are $770 (nefazodone), $1800 (CBASP)
and $2500 (combination). Estimated mean direct treat-
ment costs per acute responder are $1700 (nefazodone),
$4000 (CBASP), and $3400 (combination). Multivariate
results are presented that highlight the interrelationships
of treatment modality, disease severity (HAM-D), func-
tional status (SAS, SF-36, and L.I.F.E.) and costs of treat-
ment. CONCLUSIONS: Combination treatment is most
efficacious. Direct treatment cost per acute responder is
lowest for treatments using nefazodone. Further cost-effec-
tiveness results incorporating variation in time-to-response,
other direct costs, and economic benefits associated with
treatment will also be presented.
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OBJECTIVES: Parkinson’s disease is a progressive neu-
rodegenerative disease and important contributor to dis-
ability. We demonstrated health care status, utilization of
health services and total direct costs of Parkinson’s dis-
ease. METHODS: We used a prevalence approach and
aggregate national data sources to determine 1997 US
annual direct medical cost and general health status of
Parkinson’s patients from a societal perspective. A sensi-
tivity analysis varied prevalence and utilization of each
cost factor around a base case. RESULTS: The preva-
lence of idiopathic Parkinson’s disease is 283/100,000
population, of which 82% are greater than 65 years.
Only 3% of the population with Parkinson’s disease re-
port that they are in excellent health, 11% very good,
19% good, 29% fair and 38% in poor health. Total di-
rect costs are $6.6 billion, $3.4 billion for men. Nursing
home costs ($2.9 billion) account for the largest propor-
tion (44%) of these costs, with medications second
($1.95 billion, 29%) and hospitalizations third most
costly ($1.1 billion, 17%). This is about $8,738 per per-
son annually. The elderly carry the greatest cost burden,
highest for the 75–84 year olds ($2.6 billion annually).
Sensitivity analysis showed a maximum variation in cost
from $3.3 to $9.4 billion when varying both utilization
and prevalence estimates. CONCLUSIONS: The societal
cost burden is high considering the low prevalence of the
disease. Other chronic diseases generally cost only $1–
2,000 annually per patient. There is a large self-perceived
health burden, with the majority of patients reporting
“poor” health status. This study demonstrates a high
combined economic and social burden for Parkinson’s
disease patients.
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OBJECTIVE: To assess factors that influence whether
patients with schizophrenia are prescribed second-gener-
ation antipsychotic medications (olanzapine, risperidone)
or traditional antipsychotics. METHODS: Data were ob-
tained from the Schizophrenia Care and Assessment Pro-
gram study. Participant information was collected through
interviews and medical record abstraction (n  294).
Treating physicians were surveyed about their demo-
graphic, professional, and practice characteristics (n 
42). Patient and physician information was linked. Mul-
tivariate logistic regression with patient and physician-
level predictors was estimated. RESULTS: The following
variables were positively associated with second-genera-
tion medication use at P  0.05: a higher baseline
PANSSNS score (e.g. depressed affect), having a physi-
cian who has been in practice less than five years or
greater than 20 years, one who has attended more than
one professional meeting in the last five years, and one
who sees more than 25 patients a week. The following
variables were positively associated with second-genera-
tion medication use at P  0.1 in some of the models: pa-
tient age 35, race other than African-American or White,
diagnosis of other schizophrenia, being uninsured, and
having one or no prior psychotic episodes. Medicare, Med-
icaid, private insurance, CHAMPUS, and other insurance
were not significant predictors. CONCLUSIONS: One of
the perceived advantages of second-generation antipsy-
chotic medications over traditional antipsychotics is their
greater effectiveness at reducing the negative symptoms
of schizophrenia. Consistent with this belief, we find that
physicians are prescribing second-generation antipsy-
chotics to patients who display more negative symptoms.
There is also evidence that physicians may be prescribing
second-generation antipsychotics to younger patients and
those experiencing a first psychotic episode, thus using
second-generation medications as first-line treatments.
We also find that physician characteristics are influencing
whether patients are being prescribed the second-genera-
tion medications. Finally, we do not find evidence that
insurance status influences access to medications.
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OBJECTIVE: To observe patterns of antidepressant use
and concomitant psychotropics as an index of clinical
prescribing practice. METHODS: Among 1.6 million
members of Merck-Medco followed continuously be-
tween 1/1/96–12/31/98, we identified all patients (N 
42,510) who received a new antidepressant prescription
(defined as none within the prior 12 months) in 1997 (In-
dex AD). We observed the time between the use of other
concomitant psychotherapeutics (e.g. conventional anti-
psychotics (AP)/atypical antipsychotics (AP-A), benzodi-
azepine, anxiolytics (ANX)/buspirone (ANX-B), sedative/
hypnotics (SH) and zolipidem (SH-Z)) in the year prior
to or year after the index AD prescription. RESULTS:
14,792 (34.8%) AD patients were prescribed a concomi-
tant psychotherapeutic agent. All classes of concomitant
psychotherapeutics revealed a similar general pattern: a
steady increase in daily use in the year prior to an index
AD, a peak on the index AD date, and a tapering over the
next year. However, patients were more likely to receive
a conventional antipsychotic and anxiolytic prior to the
index AD, and an atypical antipsychotic and buspirone
after the index AD.
CONCLUSIONS: Whereas we hypothesized excessive
benzodiazepine and hypnotic usage pre- and post-index
AD, we noted lower than expected usage. We did not ex-
pect the pattern of increased atypical antipsychotic usage
on the same day or subsequent to an index AD. We spec-
ulate that continuing medical education of physicians
may be contributing to a decrease in the putative misuse
of benzodiazepines and hypnotics.
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Concomitant % of AD patients
Pre-Index 
AD (cumulative-1yr)
AP 2.28 .87
AP-A 2.36 .58
ANX 21.30 12.30
ANX-B 3.73 1.58
SH 5.73 2.98
SH-Z 8.96 4.25
Concomitant Same Day
Post-Index 
AD (cumulative-1 yr)
AP .30 1.12
AP-A .38 1.40
ANX 1.99 7.00
ANX-B .36 1.79
SH .37 2.37
SH-Z .75 3.97
BACKGROUND: The California Medicaid program
(Medi-Cal) added fluoxetine and paroxetine to its formu-
lary in May 1996. OBJECTIVES: This study evaluated
the impact of this policy change on the number of pa-
tients seeking treatment, treatment completion rates and
the cost of treating depressed patients. METHODS: All
patients with a recorded diagnosis of major depression
(MDD) between 09/01/1994 and 12/31/1997 were se-
lected from the Medi-Cal paid claims system. Completed
therapy required 180 days of uninterrupted therapy at an
adequate dose as estimated from drug claims. Multivari-
ate statistical models of treatment completion and direct
health care costs were estimated. RESULTS: The policy
change resulted in an immediate increase in the number
of new antidepressant drug therapy episodes initiated per
month (woodwork effect), but only for the newly added
drugs. The prior use profile of treated patients exhibited
a significant time trend toward higher prior use and com-
pleted therapy rates decreased for all products. Patients
treated initially with fluoxetine and sertraline were signif-
icantly more likely to complete therapy than TCA pa-
tients (odds ratios: 4.73 before change, 2.10 after for flu-
oxetine; 2.15 and 1.24 for sertaline, respectively).
Completion rates for paroxetine were not statistically
different from TCAs (odds ratios: 1.27, P  0.3147 be-
fore and 1.017, P  0.3943 after). Completed therapy
was associated with reductions in ambulatory care costs
in both periods. However, increased drug costs com-
pletely offset these savings after the formulary change.
CONCLUSION: The change in Medi-Cal formulary pol-
icy adding fluoxetine and paroxetine may have provided
new treatment options for more severely ill, refractory
patients that may have resulted in a modest increase in
costs.
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Osteoporosis affects over 28 million Americans, causing
over $13.8 billion in healthcare costs annually. Aging of
the population is expected to increase the national bur-
den of osteoporosis, though little is known about state
level impacts. In Florida, there is a large and growing at-
risk population (6.2 million age 45 and 2.7 million age
65). In 1998, there were 25,000, 4500, 1600 and
12,500 hip, vertebral, forearm/wrist and other fracture
hospitalizations, respectively. OBJECTIVE: To predict
the costs of osteoporosis in Florida over the next decade.
METHODS: Inpatient costs were estimated from Florida
hospital discharge data and primary and long-term care
costs were obtained from published national estimates.
Costs of osteoporosis for women age 50–100 were pre-
